glejak mózgu

[weronika-pl]

Mój 32l mąż jest trzy miesiące po operacj guza mózgu - gważdziaka
włókienkowego (astrocytoma fibrilllare II). W chwili obecnej
przechodzi radioterapię. Czy może ktoś z Was, lub Waszych bliskich
miał tego rodzaju guza, na czym polegało leczenie po operacji, czy
ktoś z Was zażywał Temodal po jednokrotnym usunięciu guza? Bardzo
proszę o informacje.

[polimeraska]

Niesamowitym, niezwykle obiecującym przykładem zastosowania z
sukcesem terapii z udziałem RNAi (z zastosowaniem technologii
interferencji RNA) podzielił się na wykładzie prof. Barciszewski z
Instytutu Chemii Bioorganicznej PAN, który wraz ze swoim zespołem
opracował metodę leczenia glejaków, tj. złośliwych nowotworowych
guzów mózgu, o bardzo szybkim przebiegu klinicznym, które należą do
najtrudniejszych w leczeniu, właśnie z uwagi na bardzo szybki
rozrost. Ta obiecująca metoda polega na podawaniu do przestrzeni
poperacyjnej po wycięciu nowotworu, długiego - dwuniciowego RNAi o
sekwencji komplemantarnej do genu kodującego białko tenascynę-C, co
powoduje zahamowanie ekspresji tego genu, poprzez degradację mRNA
kodującego wspomniane białko, które u osób z glejakiem mózgu
występuje w dużych ilościach w surowicy krwi. Okazuje się, że u
wielu osób leczonych tą metodą nie nastąpił ponowny rozrost, ale
wyleczenie. Z uwagi na obiecujące wyniki metoda ta jest
dopracowywana, a badania są kontynuowane.

[margit35]

Witaj napisałam na pocztę gazety,mamy bardzo podobne historie ,mój mąż miał ten
sam rodzaj i stopień glejaka i jest już 6 lat po zabiegu i radioterapii trzymaj
się pozdrawiam

[scept89]

Znalazlem tylko ten artykul traktujacy m.i o astrocytoma grade II:

David G Walker, Andrew H Kaye (2001)
Diagnosis and management of astrocytomas, oligodendrogliomas and mixed gliomas:
A review
Australasian Radiology 45 (4), 472–482.

Niestety jest on dosc stary i w ciagu 6 lat postepowanie moglo sie zmienic, ale
z cala pewnoscia rokowanie nie jest gorsze niz bylo 6 lat temu. W cancernet
informacji tez nie jest za wiele:
www.cancer.gov/cancertopics/pdq/treatment/adultbrain/HealthProfessional/83.cdr#Section_83

Pozdrawiam

Wklejam tylko fragment artykulu bo calosc nie zmiesci sie w okienku:
Low-grade astrocytomas (LGA) are common brain neoplasms that primarily affect
young adults. Although these patients often have a reasonably long survival,
most patients will ultimately succumb to their tumours. Low-grade astrocytomas
are slow-growing astrocytic neoplasms with a high degree of cellular
differentiation that diffusely infiltrate nearby brain. These lesions generally
affect young adults and have a tendency to progress to higher-grade
astrocytomas. The management of LGA, in terms of making a diagnosis, the timing
and extent of surgery and the benefits of adjuvant therapy, remain
controversial. The evidence for alternative management approaches is presented
in this review.

The term astrocytoma, unless otherwise specified, usually refers to low-grade
diffuse astrocytomas of adulthood. Some authors refer to these as
‘well-differentiated astrocytoma’ or ‘fibrillary astrocytoma’,1 but this latter
designation is used more commonly for the respective histological subtype of
LGA. Low-grade astrocytomas must be differentiated from pilocytic astrocytomas,
which have a different age distribution, location and biology.

<snip>

Prognostic factors
Clinical and surgical factors

The median survival time after surgical intervention is in the range of 6–8
years, with marked variation. Many studies have been published on the subject of
prognostic factors for LGA. For instance, in the largest study published to
date, Laws et al. found the following factors important to prolonged survival:
(i) gross total surgical removal; (ii) lack of preoperative neurological
deficit; (iii) long duration of symptoms prior to surgery; (iv) seizures as a
presenting symptom; and (v) having had surgery in recent decades.5

Almost all authorities would agree that young age at the time of diagnosis is by
far the most important factor correlating with long survival.5,23-29 Seizures
are correlated with a better prognosis while focal deficit and change in
personality are indicative of a worse prognosis.5,29,30 The beneficial effect of
a good clinical condition at diagnosis is well documented.5,17,24 Hence,
patients who present with a focal neurological deficit29 or with evidence of
raised intracranial pressure with papilloedema have a worse outlook than those
presenting with epilepsy.5,16

A recent study combining the results from three institutions identified
pretreatment factors to be the most important in terms of predicting outcome.31
Using these factors (i.e. age < 40 years, Karnofsky performance score > 70 and
absence of enhancement on CT or MRI), these investigators identified four groups
of patients with statistically different median survivals. The extent of surgery
and whether radiotherapy was immediate or delayed did not affect survival.

The effect of the extent of surgery on survival for patients with LGA is
controversial. Soffietti et al. found a longer survival in those with gross
surgical removal,29 but others have not found that the extent of surgical
resection corresponds with the length of survival.16,31,32 Most, but not all,
studies have indicated that patients who receive a biopsy only have a worse
survival compared to resection.17,18

<snip>

Outcome and conclusions

Before the MRI era, studies would indicate that a typical 5 year survival rate
is approximately 40–50% and a 10 year survival rate is 20–30%.5 Two recent
studies may indicate that early diagnosis with CT and MR imaging may improve
survival, with a median survival rate now of 7.5 years and a 5 year survival of
65% and 10 year survival of 40%.17,25 This does not imply, however, that earlier
diagnosis has had any impact on the natural history of the disease.

The management of LGA is controversial and outcome is dependent on multiple
factors, not only on the treatment instituted but also the variable intrinsic
biology of the tumours themselves. We would recommend tissue diagnosis in all
cases of suspected LGA. In patients with surgically accessible tumours, or those
with mass effect on imaging and clinical grounds, craniotomy and cytoreductive
surgery should be instituted. Stereotactic biopsy only is a viable option in
tumours in eloquent regions with no mass effect or enhancement on imaging. In
general, radiation therapy can be delayed until there is evidence of progressive
or recurrent disease. A more aggressive early approach is recommended for those
who are over 40 years of age, who clinically have neurological impairment or
raised intracranial pressure, or who have enhancing tumours on CT or MR imaging.

[margit35]

Hej strasznie ciekawi mnie ten artykuł czy ktoś ma może trochę czasu i
cierpliwości ,żeby go przetłumaczyć?bardzo proszę bo tam coś pisze chyba o
okresach przeżyć i prognozach